Vancomycin - All About

Treatments, possible treatments, unsubstantiated/unproven treatments. Consult your doctor first.
Guest

Postby Guest » Tue Nov 25, 2003 11:26 pm

YEAH! I just wanted to report back that the pulsing worked for our little girl. Finally, we have a break from this nasty stuff. Thanks a ton for anyone who wrote about pulsing. The doctors were so reluctant (egos) but we emphasized that we really wanted to try this AND it worked. Last Flagyl dose was on Halloween and we just had our first neg c-diff last week.

Bobbie
Administrator
Posts: 12688
Joined: Sat Aug 06, 2005 8:00 pm

Postby Bobbie » Wed May 31, 2006 10:34 pm

Marcia,
I just glanced at the article you posted. I think it says ViroPharma is upset because if a generic Vancocin is approved, they will lose their exclusive rights and thus $$$. Perhaps they are concerned about the quality of a generic type, and perhaps not. Drug companies need to make money, but when they lose the patent (or whatever it's called-- used to know), they have competition and thus less profit.

Lauren
Administrator
Posts: 385
Joined: Tue Jul 12, 2005 10:23 pm

Postby Lauren » Tue Sep 05, 2006 6:12 pm

New vancocin information contributed by Allison:

Pharmacology and chemistry
It is a branched tricyclic glycosylated nonribosomal peptide produced by the fermentation of the Actinobacteria species Amycolatopsis orientalis (formerly designated Nocardia orientalis).

Vancomycin acts by inhibiting proper cell wall synthesis in Gram-positive bacteria. The mechanism inhibited, and various factors related to entering the outer membrane of Gram-negative organisms mean that vancomycin is not active against Gram-negative bacteria (except some non-gonococcal species of Neisseria).

Specifically, vancomycin prevents incorporation of N-acetylmuramic acid (NAM)- and N-acetylglucosamine (NAG)-peptide subunits into the peptidoglycan matrix; which forms the major structural component of Gram-positive cell walls.

The large hydrophilic molecule is able to form hydrogen bond interactions with the terminal D-alanyl-D-alanine moieties of the NAM/NAG-peptides. Normally this is a five-point interaction. This binding of vancomycin to the D-Ala-D-Ala prevents the incorporation of the NAM/NAG-peptide subunits into the peptidoglycan matrix.

Vancomycin exhibits atropisomerism — it has two chemically distinct rotamers owing to the rotational restriction of the chlorotyrosine residue (on the right hand side of the figure). The form present in the drug is the thermodynamically more stable conformer, and, importantly, has more potent activity.

Reprinted with permission.
http://en.wikipedia.org/wiki/Vancomycin


Return to “Treatments”



Who is online

Users browsing this forum: No registered users and 60 guests